Tesamorelin
Tesamorelin

Home

/

Shop

/

Tesamorelin

Tesamorelin
Tesamorelin
Tesamorelin
Tesamorelin
Tesamorelin
Tesamorelin

Tesamorelin

£25.00Sold out
Out of stock
Size
1
ABOUT THIS COMPOUND
Description

Tesamorelin from Super Human Peptides UK is a highly advanced, synthetic analogue of endogenous Growth Hormone-Releasing Hormone (GHRH). It consists of the full 44-amino acid sequence of human GHRH, engineered with a specific trans-3-hexenoic acid group attached to the N-terminus. In laboratory research, Tesamorelin is the premier model for investigating the reduction of visceral adipose tissue (VAT) and the modulation of lipid profiles.

The unique N-terminal modification is critical: it protects the peptide from rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), significantly extending its half-life and biological activity compared to standard GHRH fragments like Sermorelin. Produced under GMP-compliant conditions and verified for 99% purity or higher, Tesamorelin allows researchers to study profound, targeted fat mobilization while preserving the body's natural somatotropic feedback loops.

WarningFor laboratory research use only. Not for human consumption.
Key Features
  • —Modified GHRH Analogue: Full 44-amino acid sequence with a trans-3-hexenoic acid addition.
  • —Enzymatic Resistance: Specifically engineered to resist rapid degradation by DPP-4 enzymes.
  • —Visceral Fat Targeting: The primary peptide model utilized for researching lipodystrophy and visceral adiposity.
  • —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
  • —Quality Standard: GMP / ISO certified manufacturing.
Research Focus
  • —Visceral Adiposity: Studying the targeted mobilization and oxidation of visceral adipose tissue (VAT) under metabolic stress.
  • —DPP-4 Resistance: Investigating how N-terminal modifications alter pharmacokinetics and extend the half-life of natural hormone analogues.
  • —Lipid Profile Modulation: Measuring the reduction of triglycerides and the improvement of cholesterol ratios in models of diet-induced obesity or lipodystrophy.
  • —Cognitive Function: Emerging preclinical models exploring the peptide's ability to improve executive function and memory in age-related cognitive decline (MCI).
  • —Endocrine Feedback: Researching the preservation of the natural negative feedback loop via somatostatin, ensuring GH levels remain within a physiological range.
Published Research and Study Findings

Tesamorelin was developed specifically to address the severe visceral fat accumulation and metabolic abnormalities associated with HIV-related lipodystrophy. Laboratory and clinical literature extensively documents its unique mechanism: by binding to GHRH receptors on the pituitary, it stimulates a highly sustained, natural pulse of growth hormone. Landmark studies by Falutz et al.

demonstrated that Tesamorelin produces highly targeted metabolic effects. Unlike exogenous human growth hormone (hGH), which can cause severe insulin resistance and generalized tissue growth, Tesamorelin administration in animal and clinical models specifically reduces visceral fat by up to 15-20% while actually improving lipid profiles and preserving insulin sensitivity. Because its trans-3-hexenoic acid shield allows it to survive in the bloodstream much longer than natural GHRH, it remains a heavily studied compound in metabolic syndrome, cardiovascular risk reduction, and gerontology research.

NoteAll findings are derived from laboratory and non-clinical research settings.
Representative Scientific References
  • 1.Falutz, J. et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," The New England Journal of Medicine, 2007.
  • 2.Clemmons, D.R. et al., "Efficacy and safety of tesamorelin, a growth hormone-releasing factor analogue, in HIV-associated lipodystrophy," The Journal of Clinical Endocrinology and Metabolism, 2014.
  • 3.Baker, L.D. et al., "Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults," Archives of Neurology, 2012.
  • 4.Ferdinandi, E.S. et al., "Pharmacokinetics and pharmacodynamics of tesamorelin, a growth hormone-releasing factor analogue, in healthy volunteers," Clinical Pharmacokinetics, 2007.
Technical data
Specifications
Purity
≥99%, HPLC verified
Form
Lyophilised white powder
Molecular formula
C211H366N72O67S
Molecular weight
5135.9 g/mol
SKU
SHP-TESA-002
Research category
Secretagogues
Storage
-20°C, protected from light
Reconstitution
Reconstitute with bacteriostatic water; swirl gently, do not shake
Research use
In-vitro laboratory research only. Not for human consumption.
Common questions
Frequently asked questions
Tesamorelin is a synthetic 44-amino-acid GHRH analogue with a trans-3-hexenoic acid N-terminal modification that confers resistance to DPP-4 degradation. It is supplied lyophilised at ≥99% purity.
It is studied in visceral adiposity and lipid profile models, in DPP-4 resistance investigation, and where researchers want somatotropic feedback regulation preserved rather than bypassed.
Tesamorelin is supplied at ≥99% purity, verified by HPLC with mass-spectrometry identity confirmation. Testing is carried out per batch rather than per product line, so the figures on your certificate of analysis relate to the exact lot in your vial.
Store the sealed vial at -20°C, protected from light. Once reconstituted, the solution should be kept refrigerated at 2-8°C, protected from light, and treated as a short-lived working preparation rather than a long-term stock.
Tesamorelin is supplied lyophilised. Reconstitute with bacteriostatic water; swirl gently, do not shake, and allow the powder to dissolve fully before use. Direct the solvent down the inside wall of the vial rather than onto the pellet, and record the volume used so working concentrations can be calculated. This applies to in-vitro laboratory work only.
Both are GHRH-based. Sermorelin Acetate is the shortest fully functional fragment, GHRH 1-29, and is degraded rapidly; Tesamorelin carries the full 44-residue sequence plus a modification that resists DPP-4, giving a longer half-life in research models. Sermorelin is the usual choice for short-duration pulsatility work, Tesamorelin where extended exposure is wanted.
Yes. A certificate of analysis covering HPLC purity and mass-spectrometry identity is available for every batch of Tesamorelin. Each vial carries a batch number on its label, and quoting that number lets us send you the certificate that matches the material you hold rather than a generic example.
Tesamorelin has the molecular formula C211H366N72O67S and a molecular weight of 5135.9 g/mol. Those figures are stated on the certificate of analysis supplied with each batch and are the values researchers use when preparing molar calculations.
Tesamorelin ships from the UK to UK research addresses, with tracked dispatch and insulated packaging. It is sold for in-vitro laboratory research only: it is not a medicine, not a supplement, and not for human or veterinary consumption. Orders are accepted on the basis that the buyer is a qualified researcher.